Your browser doesn't support javascript.
loading
Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.
Farhadfar, Nosha; Hsu, Jack W; Logan, Brent R; Sees, Jennifer A; Chitphakdithai, Pintip; Sugrue, Michele W; Abdel-Azim, Hisham; Anderlini, Paolo N; Bredeson, Christopher; Chhabra, Saurabh; Diaz, Miguel Angel; Ganguly, Siddhartha; Hematti, Peiman; Kamble, Rammurti T; Kasow, Kimberly A; Lazarus, Hillard M; Lynch, Debra Kelly; Murthy, Hemant S; Olsson, Richard F; Papari, Mona; Przepiorka, Donna; Savani, Bipin N; Schears, Raquel; Seo, Sachiko; Solh, Melhem M; Spitzer, Thomas; Yared, Jean A; Pulsipher, Michael A; Shah, Nirali N; Switzer, Galen E; Confer, Dennis L; Shaw, Bronwen E; Wingard, John R.
Afiliação
  • Farhadfar N; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
  • Hsu JW; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
  • Logan BR; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, and.
  • Sees JA; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI.
  • Chitphakdithai P; CIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
  • Sugrue MW; CIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
  • Abdel-Azim H; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
  • Anderlini PN; Children's Hospital of Los Angeles, Los Angeles, CA.
  • Bredeson C; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chhabra S; Ottawa Hospital Blood and Marrow Transplant Program and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Diaz MA; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Ganguly S; Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
  • Hematti P; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
  • Kamble RT; Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI.
  • Kasow KA; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.
  • Lazarus HM; Pediatric Hematology Oncology Program, University of North Carolina, Chapel Hill, NC.
  • Lynch DK; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH.
  • Murthy HS; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
  • Olsson RF; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
  • Papari M; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Przepiorka D; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
  • Savani BN; ITxM Clinical Services Cord Blood Laboratory, Rosemont, IL.
  • Schears R; Center for Biologic Evaluation and Research, US Food and Drug Administration, North Potomac, MD.
  • Seo S; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Solh MM; Department of Emergency Medicine, Mayo Medical School, Rochester, MN.
  • Spitzer T; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
  • Yared JA; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
  • Pulsipher MA; Massachusetts General Hospital, Boston, MA.
  • Shah NN; Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.
  • Switzer GE; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA.
  • Confer DL; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Shaw BE; Department of Medicine, University of Pittsburgh, Pittsburgh, PA; and.
  • Wingard JR; CIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
Blood Adv ; 4(4): 706-716, 2020 02 25.
Article em En | MEDLINE | ID: mdl-32092138
ABSTRACT
There are limited data on the effect of donor body mass index (BMI) on peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimulating factor (G-CSF), especially in unrelated donors. Obesity has been associated with persistent leukocytosis, elevated circulating progenitor cells, and enhanced stem cell mobilization. Therefore, we hypothesized that adequate collection of CD34+ cells may be achieved with lower doses (per kilogram of body weight) of G-CSF in donors with higher BMI compared with donors with lower BMI. Using the Center for International Blood and Marrow Transplant Research database, we evaluated the impact of donor BMI on G-CSF-mobilized PBSC yield in healthy unrelated donors. We examined 20 884 PBSC donations collected at National Marrow Donor Program centers between 2006 and 2016. We found significantly higher collection yields in obese and severely obese donors compared with normal and overweight donors. An increase in average daily G-CSF dose was associated with an increase in stem cell yield in donors with normal or overweight BMI. In contrast, an increase in average daily G-CSF dose beyond 780 µg per day in obese and 900 µg per day in severely obese donors did not increase cell yield. Pain and toxicities were assessed at baseline, during G-CSF administration, and postcollection. Obesity was associated with higher levels of self-reported donation-related pain and toxicities in the pericollection and early postdonation recovery periods. This study suggests a maximum effective G-CSF dose for PBSC mobilization in obese and severely obese donors, beyond which higher doses of G-CSF add no increased yield.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator Estimulador de Colônias de Granulócitos / Mobilização de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator Estimulador de Colônias de Granulócitos / Mobilização de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article